Transcriptomic and functional responses of the cystic fibrosis airway epithelium to CFTR modulator therapy.
Ontology highlight
ABSTRACT: Elexacaftor/tezacaftor/ivacaftor (ETI) cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy has led to rapid and substantial improvements in cystic fibrosis (CF) airway disease. Underlying molecular and cellular mechanisms, long-term efficacy, and ability to reverse airway epithelial remodeling in established disease remain unclear. Longitudinal nasal brushes from an adult CF cohort were used to evaluate gene expression, cellular composition, stem cell function, and microbiome changes at baseline and at 6 months and 2 years after ETI. The baseline to 6 month span showed a massive downregulation of extensive neutrophilic inflammatory gene expression programs that correlated with increased pulmonary function and decreased sinusitis. Primary airway epithelial stem cell
SUBMITTER: Vladar EK
PROVIDER: S-EPMC12643517 | biostudies-literature | 2025 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA